https://orcid.org/0000-0002-5382-5167
Key Points
Calcineurin inhibitor treatment after allo-HCT suppresses differentiation of terminal Tex and induces transitory Tex.
Transitory Tex maintains responsiveness of donor T cells to PD-1 blockade and causes cGVHD after adoptive transfer into secondary recipients.
Abstract
Calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD (cGVHD) in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory Tex), expressing both inhibitory receptors and effector molecules, into terminal Tex, and inhibited tolerance induction. Adoptive transfer of transitory Tex, but not terminal Tex, into secondary recipients developed cGVHD. Transitory Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory Tex and not terminal Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse.
References
1.
Arai
S
, Arora
M
, Wang
T
, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research
. Biol Blood Marrow Transplant
. 2015
;21
(2
):266
-274
.2.
Storb
R
, Deeg
HJ
, Pepe
M
, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial
. Br J Haematol
. 1989
;72
(4
):567
-572
.3.
Sorror
ML
, Leisenring
W
, Deeg
HJ
, Martin
PJ
, Storb
R
. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia
. Biol Blood Marrow Transplant
. 2005
;11
(10
):814
-815
.4.
Socie
G
, Stone
JV
, Wingard
JR
, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. late effects working committee of the international bone marrow transplant registry
. N Engl J Med
. 1999
;341
(1
):14
-21
.5.
Wingard
JR
, Majhail
NS
, Brazauskas
R
, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
. J Clin Oncol
. 2011
;29
(16
):2230
-2239
.6.
Zeiser
R
, Polverelli
N
, Ram
R
, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
. N Engl J Med
. 2021
;385
(3
):228
-238
.7.
Sakoda
Y
, Hashimoto
D
, Asakura
S
, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
. Blood
. 2007
;109
(4
):1756
-1764
.8.
Zeiser
R
, Blazar
BR
. Pathophysiology of chronic graft-versus-host disease and therapeutic targets
. N Engl J Med
. 2017
;377
(26
):2565
-2579
.9.
Asakura
S
, Hashimoto
D
, Takashima
S
, et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice
. J Clin Invest
. 2010
;120
(7
):2370
-2378
.10.
Flutter
B
, Edwards
N
, Fallah-Arani
F
, et al. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation
. J Clin Invest
. 2010
;120
(11
):3855
-3868
.11.
Utzschneider
DT
, Charmoy
M
, Chennupati
V
, et al. T cell factor 1-expressing memory-like cd8(+) t cells sustain the immune response to chronic viral infections
. Immunity
. 2016
;45
(2
):415
-427
.12.
Im
SJ
, Hashimoto
M
, Gerner
MY
, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
. Nature
. 2016
;537
(7620
):417
-421
.13.
Wu
T
, Ji
Y
, Moseman
EA
, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
. Sci Immunol
. 2016
;1
(6
):eaai8593
.14.
He
R
, Hou
S
, Liu
C
, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection
. Nature
. 2016
;537
(7620
):412
-428
.15.
Hudson
WH
, Gensheimer
J
, Hashimoto
M
, et al. Proliferating transitory t cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection
. Immunity
. 2019
;51
(6
):1043
-1058.e4
.16.
Belk
JA
, Daniel
B
, Satpathy
AT
. Epigenetic regulation of T cell exhaustion
. Nat Immunol
. 2022
;23
(6
):848
-860
.17.
Haverkos
BM
, Abbott
D
, Hamadani
M
, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
. Blood
. 2017
;130
(2
):221
-228
.18.
Herbaux
C
, Merryman
R
, Devine
S
, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil
. Blood
. 2018
;132
(1
):9
-16
.19.
Blazar
BR
, Carreno
BM
, Panoskaltsis-Mortari
A
, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism
. J Immunol
. 2003
;171
(3
):1272
-1277
.20.
Cooke
KR
, Kobzik
L
, Martin
TR
, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin
. Blood
. 1996
;88
(8
):3230
-3239
.21.
Ohigashi
H
, Hashimoto
D
, Hayase
E
, et al. Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD
. Blood Adv
. 2019
;3
(7
):1003
-1010
.22.
Zhang
Z
, Hasegawa
Y
, Hashimoto
D
, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation
. Bone Marrow Transplant
. 2022
;57
(5
):775
-780
.23.
Naviaux
RK
, Costanzi
E
, Haas
M
, Verma
IM
. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses
. J Virol
. 1996
;70
(8
):5701
-5705
.24.
Ono
R
, Watanabe
T
, Kawakami
E
, et al. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model
. EBioMedicine
. 2019
;41
:584
-596
.25.
Seo
H
, Gonzalez-Avalos
E
, Zhang
W
, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells
. Nat Immunol
. 2021
;22
(8
):983
-995
.26.
Chen
Y
, Zander
RA
, Wu
X
, et al. BATF regulates progenitor to cytolytic effector CD8(+) T cell transition during chronic viral infection
. Nat Immunol
. 2021
;22
(8
):996
-1007
.27.
Beltra
JC
, Manne
S
, Abdel-Hakeem
MS
, et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms
. Immunity
. 2020
;52
(5
):825
-841.e8
.28.
Khan
O
, Giles
JR
, McDonald
S
, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion
. Nature
. 2019
;571
(7764
):211
-218
.29.
Seo
H
, Chen
J
, Gonzalez-Avalos
E
, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion
. Proc Natl Acad Sci U S A
. 2019
;116
(25
):12410
-12415
.30.
Dubovsky
JA
, Flynn
R
, Du
J
, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
. J Clin Invest
. 2014
;124
(11
):4867
-4876
.31.
Miklos
D
, Cutler
CS
, Arora
M
, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
. Blood
. 2017
;130
(21
):2243
-2250
.32.
Zeiser
R
, Teshima
T
, Locatelli
F
. Ruxolitinib for chronic graft-versus-host disease. reply
. N Engl J Med
. 2021
;385
(17
):1631
-1632
.33.
Toubai
T
, Sun
Y
, Tawara
I
, et al. Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease
. Blood
. 2011
;118
(1
):192
-204
.34.
Shindo
T
, Kim
TK
, Benjamin
CL
, Wieder
ED
, Levy
RB
, Komanduri
KV
. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner
. Blood
. 2013
;121
(23
):4617
-4626
.35.
Itamura
H
, Shindo
T
, Tawara
I
, et al. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects
. JCI Insight
. 2016
;1
(10
):e86331
.36.
Herrero-Sanchez
MC
, Rodriguez-Serrano
C
, Almeida
J
, et al. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control
. Br J Haematol
. 2016
;173
(5
):754
-768
.37.
Matsuda
S
, Koyasu
S
. Mechanisms of action of cyclosporine
. Immunopharmacology
. 2000
;47
(2-3
):119
-125
.38.
Braun
LM
, Zeiser
R
. Kinase inhibition as treatment for acute and chronic graft-versus-host disease
. Front Immunol
. 2021
;12
:760199
.39.
Hermann-Kleiter
N
, Baier
G
. NFAT pulls the strings during CD4+ T helper cell effector functions
. Blood
. 2010
;115
(15
):2989
-2997
.40.
Blattman
JN
, Grayson
JM
, Wherry
EJ
, Kaech
SM
, Smith
KA
, Ahmed
R
. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo
. Nat Med
. 2003
;9
(5
):540
-547
.41.
West
EE
, Jin
HT
, Rasheed
AU
, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
. J Clin Invest
. 2013
;123
(6
):2604
-2615
.42.
Sade-Feldman
M
, Yizhak
K
, Bjorgaard
SL
, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma
. Cell
. 2018
;175
(4
):998
-1013.e20
.43.
Wu
TD
, Madireddi
S
, de Almeida
PE
, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response
. Nature
. 2020
;579
(7798
):274
-278
.44.
Burger
ML
, Cruz
AM
, Crossland
GE
, et al. Antigen dominance hierarchies shape TCF1(+) progenitor CD8 T cell phenotypes in tumors
. Cell
. 2021
;184
(19
):4996
-5014.e26
.45.
Scharping
NE
, Menk
AV
, Moreci
RS
, et al. The tumor microenvironment represses t cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction
. Immunity
. 2016
;45
(3
):701
-703
.46.
Bengsch
B
, Johnson
AL
, Kurachi
M
, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion
. Immunity
. 2016
;45
(2
):358
-373
.47.
Vaeth
M
, Maus
M
, Klein-Hessling
S
, et al. Store-operated Ca(2+) entry controls clonal expansion of T cells through metabolic reprogramming
. Immunity
. 2017
;47
(4
):664
-679.e6
.48.
Wherry
EJ
, Kurachi
M
. Molecular and cellular insights into T cell exhaustion
. Nat Rev Immunol
. 2015
;15
(8
):486
-499
.49.
Gearty
SV
, Dundar
F
, Zumbo
P
, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes
. Nature
. 2022
;602
(7895
):156
-161
.50.
Zhou
M
, Sacirbegovic
F
, Zhao
K
, Rosenberger
S
, Shlomchik
WD
. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect
. Nat Commun
. 2020
;11
(1
):4227
.51.
Daniel
B
, Yost
KE
, Hsiung
S
, et al. Divergent clonal differentiation trajectories of T cell exhaustion
. Nat Immunol
. 2022
;23
(11
):1614
-1627
.52.
Zhang
Y
, Joe
G
, Hexner
E
, Zhu
J
, Emerson
SG
. Host-reactive CD8+ memory stem cells in graft-versus-host disease
. Nat Med
. 2005
;11
(12
):1299
-1305
.53.
Sacirbegovic
F
, Gunther
M
, Greco
A
, et al. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells
. Immunity
. 2023
;56
(2
):369
-385.e6
.54.
Crawford
A
, Angelosanto
JM
, Kao
C
, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection
. Immunity
. 2014
;40
(2
):289
-302
.55.
Sekine
T
, Perez-Potti
A
, Nguyen
S
, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells
. Sci Immunol
. 2020
;5
(49
):eaba7918
.56.
Miggelbrink
AM
, Jackson
JD
, Lorrey
SJ
, et al. CD4 T-cell exhaustion: does it exist and what are its roles in cancer?
. Clin Cancer Res
. 2021
;27
(21
):5742
-5752
.57.
Tracy
SI
, Venkatesh
H
, Hekim
C
, et al. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia
. Blood
. 2022
;140
(4
):335
-348
.58.
Xia
Y
, Sandor
K
, Pai
JA
, et al. BCL6-dependent TCF-1(+) progenitor cells maintain effector and helper CD4(+) T cell responses to persistent antigen
. Immunity
. 2022
;55
(7
):1200
-1215.e6
.59.
Raiola
AM
, Angelucci
E
, Sica
S
, Bacigalupo
A
. Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: the Genova protocol
. Blood Rev
. 2022
:101031
.60.
Luznik
L
, O'Donnell
PV
, Symons
HJ
, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
. Biol Blood Marrow Transplant
. 2008
;14
(6
):641
-650
.61.
Minnie
SA
, Waltner
OG
, Ensbey
KS
, et al. Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity
. Sci Immunol
. 2022
;7
(76
):eabo3420
.62.
Bachireddy
P
, Hainz
U
, Rooney
M
, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion
. Blood
. 2014
;123
(9
):1412
-1421
.63.
Liu
L
, Chang
YJ
, Xu
LP
, et al. Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT
. Biol Blood Marrow Transplant
. 2018
;24
(7
):1350
-1359
.© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal